News | July 14, 2011

Endosense, Siemens Complete First Case Using Jointly Developed Contact-Force Visualization


July 14, 2011 – Endosense, a Swiss medical technology company, announced completion of the first patient case using prototype software integrating the contact-force data provided by Endosense’s TactiCath force-sensing ablation catheter with Siemens Healthcare’s electrophysiology solutions.

Performed by Dipen Shah, M.D.,  June 15, 2011, at the University Hospital of Geneva, this procedure demonstrated the feasibility of the companies’ jointly developed application for use during the catheter ablation treatment of cardiac arrhythmias.

The new software was designed to give electrophysiologists access to contact-force information in a fluoroscopically enabled, three-dimensional anatomic heart model with X-ray based catheter tracking system.

“This new contact-force visualization software brings a valuable new sensory dimension to the catheter ablation procedure, as we can now measure, control and also virtually see in 3-D the contact forces we apply as we are applying them,” said Shah. “I believe this new level of visualization will not only make the procedure more intuitive and easier for electrophysiologists to perform, but it will also allow us to improve our ablation technique in such a way that we ultimately offer safer and more effective procedures.”

 

For more information: www.siemens.com/healthcare or www.endosense.com


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now